
    
      Evaluate the safety and efficacy of RegenKit autologous PRP Gel for the treatment of diabetic
      foot ulcer is a randomized, placebo controlled, blind-assessor study. One hundred and seventy
      four patients will be treated, 87 patients receiving treatment arm and 87 patients receiving
      placebo. The primary endpoint is to evaluate proportion of patients with complete wound
      closure at week 16 when treated with autologous platelet rich plasma gel compared to the
      proportion of control (saline gel) treated patients with complete wound closure at the same
      time-point.
    
  